TMC6

Across TCGA pan-cancer cohorts, TMC6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMC6 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMC6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMC6 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where TMC6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.390	0.799	.004	14	view →
LSCC	OS	Tertile	All	1.000	0.669	.021	3	view →
PDAC	DFS	Median	III,IV	0.796	0.130	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMC6–LUAD (OS)

Open the LUAD breakdown →